Monopar Therapeutics MNPR Accounts payable and other current liabilities (Note 11)
Accounts payable and other current liabilities (Note 11) at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's accounts payable and other current liabilities (note 11).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's accounts payable and other current liabilities (note 11)?
- Monopar Therapeutics (MNPR) reported accounts payable and other current liabilities (note 11) of $2.46M in Q1 2026.
- How has Monopar Therapeutics's accounts payable and other current liabilities (note 11) changed year-over-year?
- Monopar Therapeutics's accounts payable and other current liabilities (note 11) increased by 64.7% year-over-year, from $1.49M to $2.46M.
- What is the long-term trend for Monopar Therapeutics's accounts payable and other current liabilities (note 11)?
- Over 5 years (2020 to 2025), Monopar Therapeutics's accounts payable and other current liabilities (note 11) has grown at a 18.4% compound annual growth rate (CAGR), from $1.18M to $2.74M.